Total Payments
$17,831
2024 Payments
$2,206
Companies
7
Transactions
18
Medicare Patients
1,287
Medicare Billing
$327,379
Payment Breakdown by Category
Research$11,626 (65.2%)
Other$3,000 (16.8%)
Consulting$2,100 (11.8%)
Travel$603.72 (3.4%)
Food & Beverage$468.61 (2.6%)
Education$32.94 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,626 | 3 | 65.2% |
| Honoraria | $3,000 | 2 | 16.8% |
| Consulting Fee | $2,100 | 1 | 11.8% |
| Travel and Lodging | $603.72 | 3 | 3.4% |
| Food and Beverage | $468.61 | 7 | 2.6% |
| Education | $32.94 | 2 | 0.2% |
Payments by Type
Research
$11,626
3 transactions
General
$6,205
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $15,579 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,100 | 1 | $0 (2024) |
| ABBVIE INC. | $74.39 | 2 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $31.80 | 2 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 1 | $0 (2020) |
| Amgen Inc. | $13.52 | 1 | $0 (2017) |
| Adaptive Biotechnologies Corporation | $13.14 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,206 | 4 | Novartis Pharmaceuticals Corporation ($2,100) |
| 2023 | $4,200 | 2 | PFIZER INC. ($4,200) |
| 2022 | $8,939 | 3 | PFIZER INC. ($8,926) |
| 2020 | $1,519 | 2 | PFIZER INC. ($1,500) |
| 2018 | $953.20 | 6 | PFIZER INC. ($921.40) |
| 2017 | $13.52 | 1 | Amgen Inc. ($13.52) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $31.60 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Oncology | ||||||
| 05/21/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $41.76 | General |
| Category: ONCOLOGY | ||||||
| 04/06/2023 | PFIZER INC. | DAURISMO (Drug) | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB PF04449913 OR AZACITIDINE AZA WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA • Category: ONCOLOGY | ||||||
| 03/15/2023 | PFIZER INC. | DAURISMO (Drug), MYLOTARG | — | In-kind items and services | $3,200.00 | Research |
| Study: GLASDEGIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/15/2022 | PFIZER INC. | DAURISMO (Drug) | — | Cash or cash equivalent | $7,425.60 | Research |
| Study: A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB PF04449913 OR AZACITIDINE AZA WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA • Category: ONCOLOGY | ||||||
| 07/01/2022 | PFIZER INC. | BOSULIF (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 05/26/2022 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 10/01/2020 | E.R. Squibb & Sons, L.L.C. | INREBIC (Drug) | Education | Cash or cash equivalent | $19.42 | General |
| Category: Hematology | ||||||
| 09/07/2020 | PFIZER INC. | DAURISMO (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2018 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug) | Food and Beverage | Cash or cash equivalent | $18.16 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2018 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug) | Food and Beverage | Cash or cash equivalent | $13.64 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2018 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $336.30 | General |
| 04/22/2018 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $317.68 | General |
| 04/22/2018 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $153.42 | General |
| 04/22/2018 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $114.00 | General |
| 05/17/2017 | Amgen Inc. | Blincyto (Biological) | Education | In-kind items and services | $13.52 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB PF04449913 OR AZACITIDINE AZA WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA | PFIZER INC. | $8,426 | 2 |
| GLASDEGIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 361 | 888 | $517,921 | $91,336 |
| 2022 | 8 | 327 | 804 | $455,575 | $81,747 |
| 2021 | 8 | 320 | 883 | $395,401 | $89,338 |
| 2020 | 8 | 279 | 711 | $317,765 | $64,959 |
Total Patients
1,287
Total Services
3,286
Medicare Billing
$327,379
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 89 | 290 | $199,810 | $32,404 | 16.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 232 | $106,720 | $25,196 | 23.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 127 | 243 | $120,042 | $18,250 | 15.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 41 | 55 | $53,845 | $8,756 | 16.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $19,257 | $2,816 | 14.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 36 | $11,592 | $2,600 | 22.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $6,655 | $1,314 | 19.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 236 | $162,604 | $26,980 | 16.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 38 | 196 | $90,160 | $18,887 | 20.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 98 | 173 | $85,462 | $13,565 | 15.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 102 | $32,844 | $6,811 | 20.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 38 | 38 | $34,846 | $6,142 | 17.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 23 | 33 | $32,307 | $5,735 | 17.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 12 | $10,548 | $2,244 | 21.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 14 | $6,804 | $1,382 | 20.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 83 | 259 | $123,025 | $31,287 | 25.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 41 | 193 | $88,780 | $18,946 | 21.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 82 | 155 | $59,365 | $12,621 | 21.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 41 | 179 | $57,638 | $11,365 | 19.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 39 | $24,999 | $6,884 | 27.5% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Office | 2021 | 16 | 21 | $19,362 | $3,561 | 18.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $12,512 | $2,644 | 21.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 17 | 20 | $9,720 | $2,030 | 20.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 79 | 196 | $93,100 | $19,713 | 21.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 34 | 188 | $86,480 | $18,671 | 21.6% |
About Dr. Erin Jou, MD
Dr. Erin Jou, MD is a Internal Medicine healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2011. The National Provider Identifier (NPI) number assigned to this provider is 1487941985.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Erin Jou, MD has received a total of $17,831 in payments from pharmaceutical and medical device companies, with $2,206 received in 2024. These payments were reported across 18 transactions from 7 companies. The most common payment nature is "" ($11,626).
As a Medicare-enrolled provider, Jou has provided services to 1,287 Medicare beneficiaries, totaling 3,286 services with total Medicare billing of $327,379. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location New Hyde Park, NY
- Active Since 07/05/2011
- Last Updated 05/16/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1487941985
Products in Payments
- DAURISMO (Drug) $13,126
- SCEMBLIX (Drug) $2,100
- BOSULIF (Drug) $1,532
- VENCLEXTA (Drug) $74.39
- TIBSOVO (Drug) $31.80
- INREBIC (Drug) $19.42
- Blincyto (Biological) $13.52
- clonoSEQ (Device) $13.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New Hyde Park
Dr. Michael Levine, Md, MD
Internal Medicine — Payments: $394,059
Internal Medicine $394,059
Nikhil Sharma, M.d, M.D
Internal Medicine — Payments: $89,735
Internal Medicine $89,735
Nagashree Seetharamu, Md, MD
Internal Medicine — Payments: $65,767
Internal Medicine $65,767
Dr. Abhinav Agrawal, M.d, M.D
Internal Medicine — Payments: $49,576
Internal Medicine $49,576
Dr. Thomas Mathew, Md, MD
Internal Medicine — Payments: $47,542
Internal Medicine $47,542
Dr. Kennedy Omonuwa, M.d, M.D
Internal Medicine — Payments: $45,556
Internal Medicine $45,556